Back to News
Market Impact: 0.3
J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationCompany Fundamentals
Johnson & Johnson said its investigational Shockwave Javelin coronary intravascular lithotripsy catheter exceeded both primary endpoint performance goals in the pivotal FORWARD CAD study. The report is a positive clinical-development update, but the article excerpt provides no numerical results or details on the separate outcomes it mentions.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
JNJ0.75
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash